Accomplished and versatile leader with 20+ years of progressive career as Pharmaceutical/Biotech Statistician. Strategic and driven thought partner with strong technical expertise and broad therapeutic area experiences. Proven ability to build connections and manage stakeholder expectations to deliver business portfolio. Skilled and effective people leader with track record of successful people development.
COVID-19 Response Contributor Award , May 2020 US Medical Affairs, Genentech, Inc.
Recognizes employees who take the initiative beyond their normal role to contribute to the COVID efforts in a creative, innovative and impactful manner.
Outstanding Teamwork: TIMELESS study team, May 2019 US Medical Affairs, Genentech, Inc.
Outstanding Teamwork Award: recognizes a team that exemplifies the operating principles (empowered for action; partner with purpose; Genentech's Ambassador; own our business) in order to advance medical progress and impact our customers.
Outstanding Leader, April 2018 US Medical Affairs, Genentech, Inc.
Outstanding Leader: recognizes a People Manager for exhibiting unparalleled leadership by providing a vision and defining a sense of purpose for their team, serving as an inspiration and coach to colleagues, constantly providing guidance, mentorship and learning opportunities.
Yau, L. (2007), “Handling of Missing Data in Clinical Trials”, Henry Stewart Talks, Biomedical & Life Sciences Series: Design and Analysis of Randomized Clinical Trials.
Salama, C., Han, J., Yau, L. , Reiss, W.G., Kramer, B., et al. (2021), “Tocilizumab in patients hospitalized with Covid-19 pneumonia”, New England Journal of Medicine, 384(1):20-30.
Vanderlaan, M., Maniatis, A., Olney, R., Rahmaoui, A., Yau, L. , Quarmby, V., Azzolino, C., Woods, C., Moawad, D. (2020), “Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product”, Clinical Pharmacology & Therapeutics, 107(4):988-993.
Lenz, H-J., Lee, F-C., Yau, L. , Koh, A., Knost, J., Mitchell, E., Bosanac, I., Mancao, C., Parikh, A. (2016), “MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC)”, Journal of Clinical Oncology, 34(4_suppl):493-493.
Loupakis, F., Yang, D., Yau, L. , Feng, S., Cremolini, C., Zhang, W., Maus, M.K., Antoniotti, C., Langer, C., Scherer, S.J., Müller, T., Hurwitz, H.I., Saltz, L., Falcone, A., Lenz, H.J. (2015), “Primary tumor location as a prognostic factor in metastatic colorectal cancer”, Journal of the National Cancer Institute, 107(3): dju427.
Campochiaro, P., Wykoff, C., Singer, M., Johnson, B., Marcus, D., Yau, L. , Sternberg, G. (2014), “Monthly Versus As-Needed Ranibizumab Injections in Patients with Retinal Vein Occlusion; The SHORE Study”, Ophthalmology, 121(12):2432-2442.
Heier, J., Campochiaro, P., Yau, L. , Li, Z., Saroj, N., Rubio, R., Lai, P. (2012), “Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Long-term Follow-up in the HORIZON Trial”, Ophthalmology, 119:802-809.
Smith K.Y., Patel, P., Fine, D., Bellos, N., Sloan, L., Lackey, P., Kumar, P.N., Sutherland-Phillips, D.H., Vavro, C., Yau, L. , Wannamaker, P., Shaefer, M., HEAT Study Team (2009), “Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment”, AIDS, 23(12):1547-1556.
Eron Jr, J., Yeni, P., Gathe Jr, J., Estrada, V., DeJesus, E., Staszewski, S., Lackey, P., Katlama, C., Young, B., Yau, L ., Sutherland-Phillips, D., Wannamaker, P., Vavro, C., Patel, L., Yeo, J., Shaefer, M. for the KLEAN study team (2006), “The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial”, Lancet, 368:476-482.
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Job Titles Held: